Clinical trials - Solmed Clinic

Active
clinical trials

Allergology and immunology

Allergology and immunology deal with the study of allergic reactions and immune disorders. Allergists diagnose and treat allergic diseases such as hay fever, asthma, allergic dermatitis and food allergies. Immunologists monitor the immune system and treat autoimmune diseases, such as rheumatoid arthritis, and provide support for patients with weakened immune systems.

Includes patients

Hidradenitis suppurativa (IL-1 study)

Study Drug: Experimental biological therapy is a dual antagonist of interleukin-1α and interleukin-1β.

Includes patients

Atopic Dermatitis in Children (JAK-1 Study)

Study Drug: Biological therapy, JAK-1 inhibitor. The drug is already registered for the treatment of atopic dermatitis in patients over 12 years old.

Includes patients

Eosinophilic Asthma

Study Drug: Experimental drug that blocks the formation of eosinophils that cause the disease.

Includes patients

Atopic Dermatitis in Children (IL-13 Study)

Study Drug: Biological therapy that neutralizes the pro-inflammatory molecule IL-13, primarily responsible for symptoms of atopic dermatitis. The drug is already registered for treating atopic dermatitis in patients older than 12 years.

Includes patients

Rheumatoid Arthritis

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Includes patients

Hidradenitis Suppurativa (JAK-1 Study)

Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka) Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases. Main Inclusion Criteria: Patients older than 18 years who, with or …

Includes patients

Systemic Lupus Erythematosus (SLE)

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Active - does not include patients

Alopecia areata

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Active - does not include patients

Dermatomyositis

Study Drug: Experimental drug is an oral, potent, reversible, selective inhibitor of tyrosine kinase 2 (TYK2).

Active - does not include patients

Atopic Dermatitis (IL-2 Study)

Study Drug: Experimental biological therapy that neutralizes the pro-inflammatory effects of interleukin-2 (IL-2).

Finished

Lupus Nephritis

Study Drug: Experimental drug is an immunoproteasome inhibitor that selectively acts on a wide range of autoimmune diseases.

Includes patients

Hidradenitis suppurativa (IL-1 study)

Study Drug: Experimental biological therapy is a dual antagonist of interleukin-1α and interleukin-1β.

Includes patients

Atopic Dermatitis in Children (JAK-1 Study)

Study Drug: Biological therapy, JAK-1 inhibitor. The drug is already registered for the treatment of atopic dermatitis in patients over 12 years old.

Includes patients

Eosinophilic Asthma

Study Drug: Experimental drug that blocks the formation of eosinophils that cause the disease.

Includes patients

Atopic Dermatitis in Children (IL-13 Study)

Includes patients

Rheumatoid Arthritis

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Includes patients

Hidradenitis Suppurativa (JAK-1 Study)

Includes patients

Systemic Lupus Erythematosus (SLE)

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Active - does not include patients

Alopecia areata

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Active - does not include patients

Dermatomyositis

Study Drug: Experimental drug is an oral, potent, reversible, selective inhibitor of tyrosine kinase 2 (TYK2).

Active - does not include patients

Atopic Dermatitis (IL-2 Study)

Study Drug: Experimental biological therapy that neutralizes the pro-inflammatory effects of interleukin-2 (IL-2).

Finished

Lupus Nephritis

Study Drug: Experimental drug is an immunoproteasome inhibitor that selectively acts on a wide range of autoimmune diseases.

Cardiology and angiology

Cardiology focuses on the diagnosis and treatment of diseases of the heart and circulatory system, while angiology studies blood vessels. Cardiologists treat conditions such as coronary heart disease, arrhythmias, heart failure and monitor the general health of the heart. Angiologists deal with vascular diseases such as varicose veins, thrombosis and atherosclerosis and provide therapy to improve blood circulation.

Includes patients

Heart Failure with Preserved Ejection Fraction (IL-6 Study)

Study Drug: Experimental drug that reduces inflammation throughout the body, which should strengthen the heart’s function.

Includes patients

Heart Attack (Myocardial Infarction)

Study Drug: Experimental drug that slows blood clotting, an inhibitor of clotting factor XI. A low dose of this experimental drug is expected to prevent the reformation of clots at the site of previous blood vessel blockage.

Active - does not include patients

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Study Drug: Experimental drug “transfers” cholesterol from bad particles (LDL) to good particles (HDL) of cholesterol.

Active - does not include patients

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Study Drug: A drug from the PCSK9 inhibitor group, already registered for treating elevated lipids. It is available to patients who have had a myocardial infarction and, with existing medications, have excessively high LDL cholesterol. In the context of this study, the drug can be given to patients who have not had a myocardial infarction but are at a high risk of it.

Active - does not include patients

Atrial Fibrillation

Study Drug: Experimental drug that slows blood clotting, inhibitor of coagulation factor XI. This experimental drug is expected to have equal effectiveness in preventing stroke with a lower risk of bleeding, the most common side effect of this drug class.

Finished

Postural Orthostatic Tachycardia Syndrome (POTS)

Study Drug: Biological therapy that suppresses the excessive activity of B-lymphocytes that overly produce antibodies associated with this syndrome. The drug is already registered for the treatment of myasthenia gravis.

Includes patients

Heart Failure with Preserved Ejection Fraction (IL-6 Study)

Study Drug: Experimental drug that reduces inflammation throughout the body, which should strengthen the heart’s function.

Includes patients

Heart Attack (Myocardial Infarction)

Active - does not include patients

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Study Drug: Experimental drug “transfers” cholesterol from bad particles (LDL) to good particles (HDL) of cholesterol.

Active - does not include patients

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Active - does not include patients

Atrial Fibrillation

Finished

Postural Orthostatic Tachycardia Syndrome (POTS)

Dermatology

Dermatology focuses on the diagnosis and treatment of skin, hair and nail problems. Dermatologists treat acne, eczema, psoriasis, dermatitis, skin tumors and infections. They also provide prevention and protection against skin problems and help patients maintain healthy skin.

Includes patients

Hidradenitis suppurativa (IL-1 study)

Study Drug: Experimental biological therapy is a dual antagonist of interleukin-1α and interleukin-1β.

Includes patients

Atopic Dermatitis in Children (JAK-1 Study)

Study Drug: Biological therapy, JAK-1 inhibitor. The drug is already registered for the treatment of atopic dermatitis in patients over 12 years old.

Includes patients

Atopic Dermatitis in Children (IL-13 Study)

Includes patients

Hidradenitis Suppurativa (JAK-1 Study)

Includes patients

Systemic Lupus Erythematosus (SLE)

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Active - does not include patients

Alopecia areata

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Active - does not include patients

Dermatomyositis

Study Drug: Experimental drug is an oral, potent, reversible, selective inhibitor of tyrosine kinase 2 (TYK2).

Active - does not include patients

Atopic Dermatitis (IL-2 Study)

Study Drug: Experimental biological therapy that neutralizes the pro-inflammatory effects of interleukin-2 (IL-2).

Includes patients

Hidradenitis suppurativa (IL-1 study)

Study Drug: Experimental biological therapy is a dual antagonist of interleukin-1α and interleukin-1β.

Includes patients

Atopic Dermatitis in Children (JAK-1 Study)

Study Drug: Biological therapy, JAK-1 inhibitor. The drug is already registered for the treatment of atopic dermatitis in patients over 12 years old.

Includes patients

Atopic Dermatitis in Children (IL-13 Study)

Includes patients

Hidradenitis Suppurativa (JAK-1 Study)

Includes patients

Systemic Lupus Erythematosus (SLE)

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Active - does not include patients

Alopecia areata

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Active - does not include patients

Dermatomyositis

Study Drug: Experimental drug is an oral, potent, reversible, selective inhibitor of tyrosine kinase 2 (TYK2).

Active - does not include patients

Atopic Dermatitis (IL-2 Study)

Study Drug: Experimental biological therapy that neutralizes the pro-inflammatory effects of interleukin-2 (IL-2).

Endocrinology, diabetes and metabolic diseases

Endocrinology deals with hormonal disorders, and diabetology specializes in the diagnosis and treatment of diabetes. Endocrinologists monitor conditions such as disorders of the thyroid gland, adrenal glands and hormonal imbalance. Diabetologists are dedicated to controlling type 1 and 2 diabetes, monitoring blood sugar regulation and helping to prevent complications.

Active - does not include patients

Type 2 Diabetes (Amikretin Study)

Study Drug: Dual GLP-1 and amylin receptor agonist that is expected to have a stronger effect on glycemic control and reduction in body weight compared to regular GLP-1 agonists.

Active - does not include patients

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Study Drug: Experimental drug “transfers” cholesterol from bad particles (LDL) to good particles (HDL) of cholesterol.

Active - does not include patients

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Active - does not include patients

Type 2 Diabetes (Amylin Study)

Study Drug: Experimental drug containing a GLP-1 agonist and an amylin analog, expected to have a stronger effect on glycemic control and weight reduction compared to the GLP-1 agonist alone.

Active - does not include patients

Type 2 Diabetes (Amikretin Study)

Study Drug: Dual GLP-1 and amylin receptor agonist that is expected to have a stronger effect on glycemic control and reduction in body weight compared to regular GLP-1 agonists.

Active - does not include patients

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Study Drug: Experimental drug “transfers” cholesterol from bad particles (LDL) to good particles (HDL) of cholesterol.

Active - does not include patients

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Active - does not include patients

Type 2 Diabetes (Amylin Study)

Study Drug: Experimental drug containing a GLP-1 agonist and an amylin analog, expected to have a stronger effect on glycemic control and weight reduction compared to the GLP-1 agonist alone.

Gastroenterology

Gastroenterology deals with the diagnosis and treatment of diseases of the digestive system. Gastroenterologists treat conditions such as gastritis, peptic ulcer, Crohn's disease, colitis and liver cirrhosis. They provide therapy, dietary guidance and monitoring to maintain a healthy digestive system.

Includes patients

Ulcerative Colitis (IL-1 Study)

Study Drug: Patients will receive either standard biological therapy (adalimumab) or experimental biological therapy with an IL-1 proinflammatory molecule blocker.

Includes patients

Ulcerative Colitis (Vedolizumab Study)

Study Drug: Patients will receive standard biological therapy with vedolizumab or vedolizumab biosimilar.

Includes patients

Ulcerative Colitis (TL1A Study)

Study Drug: Experimental biological therapy that blocks the effect of the pro-inflammatory molecule TL1A.

Includes patients

Crohn’s Disease and Ulcerative Colitis (Dual Biological Therapy)

Study Drug: Biological therapy involving already registered drugs from the IL-23 antagonist and IL-1 antagonist groups, which will be administered alone (monotherapy) or in combination with an experimental drug from the anti-a4B7 mAb group.

Includes patients

Crohn’s Disease (TL1A Study)

Study Drug: Experimental biological therapy that blocks the effect of the pro-inflammatory molecule TL1A.

Active - does not include patients

Crohn’s Disease (Integrin Study)

Study Drug: Experimental biological therapy that blocks the proinflammatory pathway of integrin α4β. Drugs targeting the same mechanism are already registered, but the experimental drug is taken in tablet form, unlike others that are administered by infusion.

Active - does not include patients

Celiac Disease (After Short-term Gluten Consumption)

Study Drug: The experimental drug is a tissue transglutaminase 2 (TG2) blocker, an enzyme responsible for inducing inflammation in the intestines of individuals with celiac disease.

Active - does not include patients

Celiac disease

Study Drug: The experimental drug is a tissue transglutaminase 2 (TG2) blocker, an enzyme responsible for causing inflammation in the intestines of individuals with celiac disease.

Finished

Crohn’s Disease (IL-23 Study)

Study Drug: Biological therapy that blocks the pro-inflammatory molecule IL-23. The drug is already registered for a variety of other autoimmune diseases.

Includes patients

Ulcerative Colitis (IL-1 Study)

Study Drug: Patients will receive either standard biological therapy (adalimumab) or experimental biological therapy with an IL-1 proinflammatory molecule blocker.

Includes patients

Ulcerative Colitis (Vedolizumab Study)

Study Drug: Patients will receive standard biological therapy with vedolizumab or vedolizumab biosimilar.

Includes patients

Ulcerative Colitis (TL1A Study)

Study Drug: Experimental biological therapy that blocks the effect of the pro-inflammatory molecule TL1A.

Includes patients

Crohn’s Disease and Ulcerative Colitis (Dual Biological Therapy)

Includes patients

Crohn’s Disease (TL1A Study)

Study Drug: Experimental biological therapy that blocks the effect of the pro-inflammatory molecule TL1A.

Active - does not include patients

Crohn’s Disease (Integrin Study)

Active - does not include patients

Celiac Disease (After Short-term Gluten Consumption)

Study Drug: The experimental drug is a tissue transglutaminase 2 (TG2) blocker, an enzyme responsible for inducing inflammation in the intestines of individuals with celiac disease.

Active - does not include patients

Celiac disease

Study Drug: The experimental drug is a tissue transglutaminase 2 (TG2) blocker, an enzyme responsible for causing inflammation in the intestines of individuals with celiac disease.

Finished

Crohn’s Disease (IL-23 Study)

Study Drug: Biological therapy that blocks the pro-inflammatory molecule IL-23. The drug is already registered for a variety of other autoimmune diseases.

Nephrology

Nephrology deals with the diagnosis and treatment of kidney and urinary system diseases. Nephrologists monitor conditions such as chronic kidney disease, kidney stones, hypertension and kidney failure. These specialists provide therapy and advice to maintain optimal kidney function and urinary tract health.

Includes patients

IgA Nephropathy (Berger’s Disease)

Study Drug: Experimental biological therapy is an anti-TNFSF13 antibody that slows down the activity of B lymphocytes, which excessively produce IgA antibodies that are the cause of the disease.

Active - does not include patients

IgA Nephropathy (APRIL Study)

Study Drug: Experimental biological therapy that modifies the function of B lymphocytes by affecting the enzymes BLyS and APRIL within the B lymphocytes, whose excessive activity causes increased secretion of immunoglobulins and their deposition in the kidneys.

Includes patients

IgA Nephropathy (Berger’s Disease)

Study Drug: Experimental biological therapy is an anti-TNFSF13 antibody that slows down the activity of B lymphocytes, which excessively produce IgA antibodies that are the cause of the disease.

Finished

Lupus Nephritis

Study Drug: Experimental drug is an immunoproteasome inhibitor that selectively acts on a wide range of autoimmune diseases.

Includes patients

IgA Nephropathy (Berger’s Disease)

Study Drug: Experimental biological therapy is an anti-TNFSF13 antibody that slows down the activity of B lymphocytes, which excessively produce IgA antibodies that are the cause of the disease.

Active - does not include patients

IgA Nephropathy (APRIL Study)

Active - does not include patients

IgA Nephropathy (Berger’s Disease)

Study Drug: Experimental biological therapy is an anti-TNFSF13 antibody that slows down the activity of B lymphocytes, which excessively produce IgA antibodies that are the cause of the disease.

Finished

Lupus Nephritis

Study Drug: Experimental drug is an immunoproteasome inhibitor that selectively acts on a wide range of autoimmune diseases.

Neurology

Neurology focuses on the diagnosis and treatment of disorders of the nervous system. Neurologists treat conditions such as migraines, epilepsy, Parkinson's disease, multiple sclerosis and neuropathies. Their goal is to preserve the health of the brain and nerves and improve the quality of life of patients.

Trials status
Finished
All trials

Finished

Postural Orthostatic Tachycardia Syndrome (POTS)

Finished

Multiple Sclerosis (BTK Study)

Study Drug: Experimental biological therapy with Bruton’s Tyrosine Kinase inhibitor.

Finished

Postural Orthostatic Tachycardia Syndrome (POTS)

Finished

Multiple Sclerosis (BTK Study)

Study Drug: Experimental biological therapy with Bruton’s Tyrosine Kinase inhibitor.

Oncology

Oncology deals with the prevention, diagnosis and therapy of cancer. Oncologists diagnose and treat various types of tumors, including carcinomas, sarcomas, and lymphomas. Their goal is to provide comprehensive care, including surgery, chemotherapy, radiotherapy and targeted therapy, to control or cure the malignant growth.

Active - does not include patients

Squamous Cell Carcinoma of the Skin

Study Drug: Experimental immunotherapy targeting the PD-L1 pathway, enhancing lymphocytes’ ability to destroy cancer cells more effectively.

Finished

Kidney Cancer (Non-Clear Cell)

Study Drug: Within the study, patients will receive either the already registered drug sunitinib or a combination of the registered drug nivolumab and an experimental drug from the group of tyrosine kinase inhibitors.

Active - does not include patients

Squamous Cell Carcinoma of the Skin

Study Drug: Experimental immunotherapy targeting the PD-L1 pathway, enhancing lymphocytes’ ability to destroy cancer cells more effectively.

Finished

Kidney Cancer (Non-Clear Cell)

Physical medicine and rehabilitation

Trials status
Includes patients
All trials

Includes patients

Rheumatoid Arthritis

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Includes patients

Rheumatoid Arthritis

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Pulmonology

Pulmonology deals with the diagnosis and treatment of diseases of the respiratory system. Pulmonologists treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), lung infections, and respiratory allergies. Their purpose is to improve lung function and make it easier for patients to breathe.

Includes patients

Asthma

Study Drug: Experimental drug that blocks the FLAP enzyme in lung cells. This protein is responsible for the increased release of molecules that promote inflammation in individuals with asthma.

Includes patients

Eosinophilic Asthma

Study Drug: Experimental drug that blocks the formation of eosinophils that cause the disease.

Active - does not include patients

Chronic Obstructive Pulmonary Disease (COPD)

Study Drug: The experimental drug is an inhibitor of the enzyme phosphodiesterase 4 (PDE4) administered in inhalation form. This group of drugs is already registered in tablet form, and now the anti-inflammatory effectiveness of the drug is being investigated when administered as an inhalation.

Includes patients

Asthma

Study Drug: Experimental drug that blocks the FLAP enzyme in lung cells. This protein is responsible for the increased release of molecules that promote inflammation in individuals with asthma.

Includes patients

Eosinophilic Asthma

Study Drug: Experimental drug that blocks the formation of eosinophils that cause the disease.

Active - does not include patients

Chronic Obstructive Pulmonary Disease (COPD)

Other

The Solmed Polyclinic is dedicated to attracting new research projects (clinical trials) from abroad to provide an innovative approach to treatment for a greater number of patients in Croatia. If we currently lack a solution for your ailment, leave your details to receive timely notification when we can assist you.

Your stories
about us

Zlatko Jagrić

I participated in the treatment at the polyclinic. Unfortunately, the treatment did not suit me, but despite this, I remained in permanent monitoring and planned controls with Dr. Kruljac so that my health would remain under a magnifying glass in the future. I am satisfied with the approach and the staff. All praise and recommendation. Many thanks to the whole team.

Ante Svetina

I participated in the follow-up with Dr. Košec. What I can say is that I can finally breathe normally, and my nose is completely open. The staff is friendly and approachable, and the coordinator Martina was ready to answer all my questions. Center for every recommendation.

Dubravko B

I am being treated through a clinical trial with Dr. Božek. I am extremely satisfied with the effect of the treatment and the medicine itself. My sugars are finally under control. Nurses and technicians are approachable, accommodating and open to all questions. Any recommendation.

Anamarija Ledić

Big praise for the whole team at Solmed! From the beginning of the communication to the end of the therapy, everything was excellent. They are very accessible and professional, recommendations to everyone. Also, I saw that they also have a list of free treatments and services, so I recommend everyone to keep an eye on what’s on offer. Well done!

Siniša Kvakić

Big praise to the entire Solmed team for their long-term cooperation. High level of expertise and yet a warm family atmosphere for every recommendation!
See you..

Ivan Radisic

I am being treated for inflammatory bowel disease by Dr. Reigns through clinical trials. I am satisfied with the whole approach and way of working in the clinic, which is professional with a touch of casualness that makes me feel at home. Congratulations to Ivan and Damir.

All reviews

Cookie	Duration	Description
_GRECAPTCHA		Google Recaptcha service sets this cookie to identify bots to protect the website against malicious spam attacks.
cookielawinfo-checkbox-functional		Description is currently unavailable.
cookielawinfo-checkbox-obavezni		This cookie to store the user consent for the cookies in the category "Necessary".
CookieLawInfoConsent		Cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
PH_HPXY_CHECK		This cookie is used to save the information about the current session.

Cookie	Duration	Description
cookielawinfo-checkbox-advertising		Description is currently unavailable.
cookielawinfo-checkbox-ostali		Cookie to store the user consent for the cookies in the category "Other".
cookielawinfo-checkbox-other		Description is currently unavailable.

A chance for treatment innovative medicines

The course of the clinical trial

Active clinical trials

Allergology and immunology

Hidradenitis suppurativa (IL-1 study)

Atopic Dermatitis in Children (JAK-1 Study)

Eosinophilic Asthma

Atopic Dermatitis in Children (IL-13 Study)

Rheumatoid Arthritis

Hidradenitis Suppurativa (JAK-1 Study)

Systemic Lupus Erythematosus (SLE)

Alopecia areata

Dermatomyositis

Atopic Dermatitis (IL-2 Study)

Lupus Nephritis

Hidradenitis suppurativa (IL-1 study)

Atopic Dermatitis in Children (JAK-1 Study)

Eosinophilic Asthma

Atopic Dermatitis in Children (IL-13 Study)

Rheumatoid Arthritis

Hidradenitis Suppurativa (JAK-1 Study)

Systemic Lupus Erythematosus (SLE)

Alopecia areata

Dermatomyositis

Atopic Dermatitis (IL-2 Study)

Lupus Nephritis

Cardiology and angiology

Heart Failure with Preserved Ejection Fraction (IL-6 Study)

Heart Attack (Myocardial Infarction)

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Atrial Fibrillation

Postural Orthostatic Tachycardia Syndrome (POTS)

Heart Failure with Preserved Ejection Fraction (IL-6 Study)

Heart Attack (Myocardial Infarction)

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Atrial Fibrillation

Postural Orthostatic Tachycardia Syndrome (POTS)

Dermatology

Hidradenitis suppurativa (IL-1 study)

Atopic Dermatitis in Children (JAK-1 Study)

Atopic Dermatitis in Children (IL-13 Study)

Hidradenitis Suppurativa (JAK-1 Study)

Systemic Lupus Erythematosus (SLE)

Alopecia areata

Dermatomyositis

Atopic Dermatitis (IL-2 Study)

Hidradenitis suppurativa (IL-1 study)

Atopic Dermatitis in Children (JAK-1 Study)

Atopic Dermatitis in Children (IL-13 Study)

Hidradenitis Suppurativa (JAK-1 Study)

Systemic Lupus Erythematosus (SLE)

Alopecia areata

Dermatomyositis

Atopic Dermatitis (IL-2 Study)

Endocrinology, diabetes and metabolic diseases

Type 2 Diabetes (Amikretin Study)

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Type 2 Diabetes (Amylin Study)

Type 2 Diabetes (Amikretin Study)

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Type 2 Diabetes (Amylin Study)

Gastroenterology

Ulcerative Colitis (IL-1 Study)

Ulcerative Colitis (Vedolizumab Study)

Ulcerative Colitis (TL1A Study)

Crohn’s Disease and Ulcerative Colitis (Dual Biological Therapy)

Crohn’s Disease (TL1A Study)

Crohn’s Disease (Integrin Study)

Celiac Disease (After Short-term Gluten Consumption)

Celiac disease

Crohn’s Disease (IL-23 Study)

Ulcerative Colitis (IL-1 Study)

Ulcerative Colitis (Vedolizumab Study)

Ulcerative Colitis (TL1A Study)

Crohn’s Disease and Ulcerative Colitis (Dual Biological Therapy)

Crohn’s Disease (TL1A Study)

A chance for treatment
innovative medicines

Active
clinical trials

Your stories
about us